Merck, Daiichi Sankyo withdraw US application for lung cancer therapy
Merck and Daiichi Sankyo withdrew their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan, after the FDA deemed the mid-stage clinical study data insufficient. The therapy was intended for treating extensive-stage small cell lung cancer in adults who had progressed after standard chemotherapy, according to the companies.
How this was made
The 30-second read
Why it matters
Regulatory denial often leads to short‑term stock declines and reassessment of pipeline value.
Market read
Regulatory setback for a late‑stage lung cancer therapy could depress biotech equities.
What to watch
Potential for future resubmission after additional data collection.
Background
The FDA required more robust data from the mid‑stage study before granting accelerated approval.
Ticker impact
Merck withdrew its US application for the lung cancer therapy ifinatamab deruxtecan after FDA feedback.
downward pressure on MRK share price in the short term
Regulatory setback reduces near‑term revenue expectations and may affect investor sentiment.
Market effects
May weigh on biotech/oncology sector sentiment.
US biotech stocks could see broader pressure.
International investors tracking FDA outcomes may adjust exposure.
Counterpoint
The withdrawal could be strategic, preserving resources for more promising candidates.
Key entities
- CompanyMerck
US‑listed pharmaceutical giant.
- CompanyDaiichi Sankyo
Japanese pharmaceutical company with US ADR.
